The combination of an escalating metabolic epidemic and limitations of current drugs has created an enormous market opportunity for drug developers.
Today, 34% of US adults have the metabolic syndrome, a constellation of symptoms including obesity, insulin resistance and dyslipidemia. Such figures are leading industry experts to predict that the global market of metabolic drugs will reach$138bn by 2016.
The current excitement generated by the enormous cardiometabolic market potential is tempered by apparent shortcomings in currently available drug classes. New metabolic therapies will have to demonstrate mechanisms of safe and significant glycemic and lipidemic efficacy. Drug developers will also have to understand and mitigate the CV risk associated with the major metabolic diseases in order to navigate the challenging regulatory environment.
We worked closely with senior figures at Merck, Boehringer Ingelheim, Johnson & Johnson, AstraZeneca and many others to construct an agenda which will address these concerns directly. As such, this meeting promises high level, commercially directed discussion of the most pressing technical and strategic issues at hand.
Attend this meeting to:
• Get expert insight from industry clinicians on how best to satisfy regulators and speed drugs to market
• Explore mechanisms of action of the latest T2DM and obesity drug classes to optimize your own drug development
• Uncover new pathways and druggable targets to replenish the obesity and T2DM pharmaceutical pipeline
• Hear from industry experts on how best to mitigate against the CV and systemic risk associated with metabolic drugs
• Increase efficiency by hearing from the leading solution providers
Who should attend this meeting:
• Drug developers focusing on developing novel metabolic drugs
• Scientists and academics working in diabetes, obesity and dyslipidemia
• Clinicians and CROs specializing in metabolic drug trials
Further details and to register
